HRP20260406T1 - Lumateperon za primjenu u liječenju shizofrenije - Google Patents

Lumateperon za primjenu u liječenju shizofrenije

Info

Publication number
HRP20260406T1
HRP20260406T1 HRP20260406TT HRP20260406T HRP20260406T1 HR P20260406 T1 HRP20260406 T1 HR P20260406T1 HR P20260406T T HRP20260406T T HR P20260406TT HR P20260406 T HRP20260406 T HR P20260406T HR P20260406 T1 HRP20260406 T1 HR P20260406T1
Authority
HR
Croatia
Prior art keywords
lumateperone
schizophrenia
treatment
Prior art date
Application number
HRP20260406TT
Other languages
English (en)
Croatian (hr)
Inventor
Robert E. Davis
Kimberly Vanover
Original Assignee
Intra-Cellular Therapies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra-Cellular Therapies, Inc. filed Critical Intra-Cellular Therapies, Inc.
Publication of HRP20260406T1 publication Critical patent/HRP20260406T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20260406TT 2019-12-19 2020-12-18 Lumateperon za primjenu u liječenju shizofrenije HRP20260406T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962950828P 2019-12-19 2019-12-19
EP20900863.0A EP4076461B1 (en) 2019-12-19 2020-12-18 Lumateperone for use in schizophrenia treatment
PCT/US2020/066224 WO2021127572A1 (en) 2019-12-19 2020-12-18 Methods of schizophrenia treatment

Publications (1)

Publication Number Publication Date
HRP20260406T1 true HRP20260406T1 (hr) 2026-05-08

Family

ID=76437353

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20260406TT HRP20260406T1 (hr) 2019-12-19 2020-12-18 Lumateperon za primjenu u liječenju shizofrenije

Country Status (14)

Country Link
US (1) US20210186962A1 (enExample)
EP (2) EP4744678A3 (enExample)
JP (2) JP7727634B2 (enExample)
DK (1) DK4076461T3 (enExample)
ES (1) ES3067760T3 (enExample)
FI (1) FI4076461T3 (enExample)
HR (1) HRP20260406T1 (enExample)
LT (1) LT4076461T (enExample)
PL (1) PL4076461T3 (enExample)
PT (1) PT4076461T (enExample)
RS (1) RS67890B1 (enExample)
SI (1) SI4076461T1 (enExample)
SM (1) SMT202600134T1 (enExample)
WO (1) WO2021127572A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9428506B2 (en) 2012-04-14 2016-08-30 Intra-Cellular Therapies, Inc. Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders
WO2019178484A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
SMT202600133T1 (it) 2018-03-23 2026-05-12 Intra Cellular Therapies Inc Composti organici
AU2019328528B2 (en) 2018-08-31 2025-01-23 Intra-Cellular Therapies, Inc. Novel methods
JP2022549335A (ja) 2019-09-25 2022-11-24 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規方法
IL297333B2 (en) * 2020-04-17 2025-09-01 Honeybrains Llc Preparations and methods for treating neuropsychiatric disorders
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000077001A1 (en) 1999-06-15 2000-12-21 Du Pont Pharmaceuticals Company Substituted heterocycle fused gamma-carbolines
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
MX394214B (es) 2007-03-12 2025-03-24 Intra Cellular Therapies Inc Sintesis de gamma-carbolinas fusionadas con heterociclo substituido.
CA2719824A1 (en) * 2007-08-01 2009-02-05 Medivation Neurology, Inc. Methods and compositions for treating schizophrenia using antipsychotic combination therapy
ES2530090T3 (es) 2008-03-12 2015-02-26 Intra-Cellular Therapies, Inc. Sólido de gamma-carbolinas fusionadas con heterociclo sustituido
CA2725342C (en) 2008-05-27 2024-02-20 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for sleep disorders and other disorders
KR102967223B1 (ko) * 2013-12-03 2026-05-19 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
KR20220054908A (ko) 2014-04-04 2022-05-03 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
JP7013454B2 (ja) * 2016-10-12 2022-02-15 イントラ-セルラー・セラピーズ・インコーポレイテッド アモルファス固体分散体
CA3082834A1 (en) * 2017-11-22 2019-05-31 Concert Pharmaceuticals, Inc. Deuterated analogs of d-serine and uses thereof
WO2019102240A1 (en) * 2017-11-27 2019-05-31 Egis Gyógyszergyár Zrt. Method for the manufacture of lumateperone and its salts
WO2019178484A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
WO2020047408A1 (en) * 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
WO2020112941A2 (en) * 2018-11-27 2020-06-04 Teva Czech Industries S.R.O Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof

Also Published As

Publication number Publication date
EP4076461A4 (en) 2024-01-03
EP4744678A2 (en) 2026-05-20
JP7727634B2 (ja) 2025-08-21
JP2025166121A (ja) 2025-11-05
JP2023507584A (ja) 2023-02-24
LT4076461T (lt) 2026-06-25
EP4744678A3 (en) 2026-07-22
DK4076461T3 (da) 2026-02-23
WO2021127572A1 (en) 2021-06-24
EP4076461B1 (en) 2026-01-28
PL4076461T3 (pl) 2026-04-27
SI4076461T1 (sl) 2026-05-29
EP4076461A1 (en) 2022-10-26
US20210186962A1 (en) 2021-06-24
RS67890B1 (sr) 2026-04-30
PT4076461T (pt) 2026-04-16
FI4076461T3 (fi) 2026-03-24
SMT202600134T1 (it) 2026-05-12
ES3067760T3 (en) 2026-05-25

Similar Documents

Publication Publication Date Title
HUS2500039I1 (hu) Elafibranor primer biliáris cirrózis kezelésében történõ alkalmazásra
HRP20251598T1 (hr) Mavakamten za uporabu u liječenju hipertrofične kardiomiopatije
HRP20251692T1 (hr) Kombinacije inhibitora lsd1 za upotrebu u liječenju neoplastičnih bolesti
HUE058931T2 (hu) Pilokarpin hidroklorid alkalmazása presbyopia kezelésére
SI3600270T1 (sl) Spojine in sestavki za zdravljenje hematoloških motenj
SI3402888T1 (sl) Sredstva in metode za zdravljenje HBV
SI3681872T1 (sl) Heteroaril substituirani beta-hidroksietilamini za uporabo v zdravljenju hiperglikemije
HRP20251604T1 (hr) Antagonist gremlina‑1 za upotrebu u liječenju raka
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
SI3185957T1 (sl) Patisiran za uporabo pri zdravljenju s transtiretinom posredovane amiloidoze
SI3240538T1 (sl) Uporaba masitiniba za zdravljenje subpopulacije bolnikov z amiotrofično lateralno sklerozo
EP3858943A4 (en) Surface treatment agent
PL3972643T3 (pl) Antagoniści układu dopełniacza do stosowania w sposobach leczenia neuropatii paraproteinemicznych
IL271863B (en) Compounds and use thereof for the treatment of microbial infections
PL3592355T3 (pl) Kx2-391/kx-01 do zastosowania w leczeniu rogowacenia słonecznego
DK4076461T3 (da) Lumateperon til brug ved behandling af skizofreni
EP3468555C0 (en) COMPOSITIONS FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
HUE054065T2 (hu) Szerek glióma kezelésében történõ alkalmazásra
LT3706739T (lt) Riluzolo provaisto naudojimas ataksijų gydymui
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii
CY2024037I1 (el) Χρηση delgocitinib για την θεραπεια χρονιουεκζεματος χεριων
IL282313A (en) Abituzumab for the treatment of colorectal cancer
IL284124A (en) Quinoline derivatives for use in the treatment or prevention of cancer
PL3373922T3 (pl) Kompozycje i sposoby do stosowania do leczenia homocystynurii